Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder.
about
The role of the Hippo pathway in human disease and tumorigenesisYes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancerExpression of Yes-associated protein (YAP) in breast phyllodes tumor.Expression of Yes-associated protein in liver cancer and its correlation with clinicopathological features and prognosis of liver cancer patients.Prognostic Value of Yes-Associated Protein 1 (YAP1) in Various Cancers: A Meta-Analysis.YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of EnhancersYAP is a critical oncogene in human cholangiocarcinomaExpression of Yes-associated protein (YAP) in metastatic breast cancer.YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric andTeen Patients Allows Identifying Two Main Classes of Biological ProcessesInvolved and New Potential Therapeutic TargetsInhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo.Transcriptional cofactor Mask2 is required for YAP-induced cell growth and migration in bladder cancer cell.Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment.Emerging role of Hippo signalling pathway in bladder cancer.YAP/TAZ at the Roots of Cancer.Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.Promoter methylation inhibits expression of tumor suppressor KIBRA in human clear cell renal cell carcinoma.Dual roles of yes-associated protein (YAP) in colorectal cancer.YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways.Yes-Associated Protein (YAP) is a Key Factor for Improving the Management of Cancer Treatments.Clinical significance of YAP1 activation in head and neck squamous cell carcinoma.Reply: YAP is a Key Factor to Improve the Management of Cancer Treatments.ZFP226 is a novel artificial transcription factor for selective activation of tumor suppressor KIBRA.Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature.A feed forward loop enforces YAP/TAZ signaling during tumorigenesisPTEN lipid phosphatase inactivation links the hippo and PI3K/Akt pathways to induce gastric tumorigenesisMechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms
P2860
Q30433413-C1A64680-7C53-41FB-9736-C7E1E19EBF63Q33898459-EAB5C9B3-B6FC-450B-BBC9-BBDF75CD6198Q34371519-CEEEBCDE-1BFE-43F2-A91E-FC589179B0C9Q35173737-DA8CB2B1-063D-48C7-A278-5613312EEE19Q35742770-96773C2A-1C0E-4CFE-B4C4-37B648E77EF0Q35752339-FD201BCB-4A3F-4B9B-BC8A-18FD525A79E5Q36232005-51A15A8E-2C14-440A-819B-75EF412C1E91Q36261738-0151FE86-ED11-4977-9715-F609AE7DF567Q36414976-C0C0B3AD-3822-4483-8F86-313471F722D7Q36658489-341ED6B8-1029-4063-AC67-A3C50B8BE5BAQ37233609-866F9AA8-805A-47A3-B52A-5B08DC4ED438Q37427970-12053BF5-653B-4D3B-B137-372D84B1B244Q38627721-40ECF1D2-F3D2-4945-AEA8-9EBA3A47051BQ38637679-FBFD0574-C9F4-4C85-853B-4DB8C007DD9DQ38864941-21BB6B81-EA37-4D23-B739-596F27E30E64Q39003420-DD52CD2F-9E17-435B-BA53-DB9CC8536A6CQ42376523-F42DBB73-CA47-480F-9F9B-0F3347E777F2Q43651454-CC85B69D-EBC0-4DDB-B78C-F68E5DDC0F02Q47153328-E6F86EC0-EB0C-41DB-8299-428772F540C9Q47417872-DBF9CBBE-D095-4AE5-AAA7-3461B3D53B63Q47860989-B5727464-3636-46FD-B494-C7353D28EFADQ50012871-EEDF6AA5-DB4A-46BA-BCE2-EF188C07AFDEQ52663576-AF4611BC-1241-4986-83AD-B1AB04D59957Q55278953-86A4566B-BE5F-4E71-AFBC-6933FEA081EFQ55669129-0DE27637-A2DF-4BEB-AE57-97E3AEABA35FQ58695672-2EC0068E-3A5D-479D-9DBE-187FDC7B795AQ58724002-75F5B32B-C918-4E74-8B4C-A51B7B6376FFQ58787445-7F22DECF-2FFB-4D68-9F63-268D98172923
P2860
Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Overexpression of YAP 1 contri ...... lial carcinoma of the bladder.
@ast
Overexpression of YAP 1 contri ...... lial carcinoma of the bladder.
@en
Overexpression of YAP 1 contri ...... lial carcinoma of the bladder.
@nl
type
label
Overexpression of YAP 1 contri ...... lial carcinoma of the bladder.
@ast
Overexpression of YAP 1 contri ...... lial carcinoma of the bladder.
@en
Overexpression of YAP 1 contri ...... lial carcinoma of the bladder.
@nl
prefLabel
Overexpression of YAP 1 contri ...... lial carcinoma of the bladder.
@ast
Overexpression of YAP 1 contri ...... lial carcinoma of the bladder.
@en
Overexpression of YAP 1 contri ...... lial carcinoma of the bladder.
@nl
P2093
P2860
P356
P1433
P1476
Overexpression of YAP 1 contri ...... lial carcinoma of the bladder.
@en
P2093
Fang-Jian Zhou
Hsiang-Fu Kung
Huan-Xin Lin
Jia-Xing Zhang
Jian-Ye Liu
Li-Juan Jiang
Shi-Juan Mai
Yi-Ji Liao
Yi-Xin Zeng
P2860
P2888
P356
10.1186/1471-2407-13-349
P407
P577
2013-07-19T00:00:00Z
P5875
P6179
1023971978